Raloxifene has been shown to reduce the risk of invasive breast cancer in postmenopausal women, particularly those at high risk or with osteoporosis. The [STAR trial](https://www.cancer.gov/types/breast/research/star-trial) (Study of Tamoxifen and Raloxifene) provided substantial evidence, indicating that raloxifene is as effective as tamoxifen in reducing breast cancer incidence, with fewer side effects.
